Literature DB >> 23996808

Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.

Ho Cheol Hong1, Soon Young Hwang, Hae Yoon Choi, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi, Kyung Mook Choi.   

Abstract

UNLABELLED: Previous studies have shown that nonalcoholic fatty liver disease (NAFLD) and sarcopenia may share pathophysiological mechanisms, such as insulin resistance, inflammation, vitamin D deficiency, and decreased physical activity. However, their direct relationship has not been investigated. The association between NAFLD and sarcopenia was examined in 452 apparently healthy adults enrolled in the Korean Sarcopenic Obesity Study (KSOS), an ongoing prospective observational cohort study. The liver attenuation index (LAI), which was measured using abdominal computed tomography (CT), was used as a parameter for the diagnosis of NAFLD. Sarcopenia was defined using a skeletal muscle mass index (SMI) [SMI (%) = total skeletal muscle mass (kg) / weight (kg) × 100] that was measured by dual energy X-ray absorptiometry (DXA). After adjusting for age and sex, both SMI and LAI were negatively correlated with the homeostasis model assessment of insulin resistance (HOMA-IR) (P < 0.001) and high sensitivity C-reactive protein (hsCRP) (P < 0.001) as well as brachial-ankle pulse wave velocity (baPWV), an indicator of arterial stiffness. Furthermore, SMI and LAI had positive relationships with high-density lipoprotein (HDL)-cholesterol, but both had a negative relationship with triglyceride, alanine aminotransferase (ALT), and total body fat. In a multiple logistic regression analysis, the odds ratio for NAFLD risk was 5.16 (95% confidence interval [CI] = 1.63-16.33) in the lowest quartile of SMI compared to the highest after adjusting for potential confounding factors.
CONCLUSION: Individuals with lower muscle mass exhibited increased risk of NAFLD. This result may provide a novel insight into the mechanism linking between sarcopenia and NAFLD. (Clinical trial no. NCT01594710.)
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23996808     DOI: 10.1002/hep.26716

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  116 in total

1.  Low skeletal muscle mass associates with low femoral neck strength, especially in older Korean women: the Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV).

Authors:  B-J Kim; S H Ahn; H M Kim; S H Lee; J-M Koh
Journal:  Osteoporos Int       Date:  2014-11-13       Impact factor: 4.507

2.  Muscle Mass Is Linked to Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Toshifumi Yodoshi; Sarah Orkin; Ana-Catalina Arce Clachar; Kristin Bramlage; Qin Sun; Lin Fei; Andrew F Beck; Stavra A Xanthakos; Andrew T Trout; Marialena Mouzaki
Journal:  J Pediatr       Date:  2020-08       Impact factor: 4.406

3.  CT indices for the diagnosis of hepatic steatosis using non-enhanced CT images: development and validation of diagnostic cut-off values in a large cohort with pathological reference standard.

Authors:  Jieun Byun; Seung Soo Lee; Yu Sub Sung; Youngbin Shin; Jessica Yun; Ho Sung Kim; Eun Sil Yu; Sung-Gyu Lee; Moon-Gyu Lee
Journal:  Eur Radiol       Date:  2018-12-19       Impact factor: 5.315

Review 4.  Nonalcoholic Steatohepatitis, Sarcopenia, and Liver Transplantation.

Authors:  Rahima A Bhanji; Yedidya Saiman; Kymberly D Watt
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

5.  Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.

Authors:  Takashi Shida; Kentaro Akiyama; Sechang Oh; Akemi Sawai; Tomonori Isobe; Yoshikazu Okamoto; Kazunori Ishige; Yuji Mizokami; Kenji Yamagata; Kojiro Onizawa; Hironori Tanaka; Hiroko Iijima; Junichi Shoda
Journal:  J Gastroenterol       Date:  2017-08-08       Impact factor: 7.527

Review 6.  Sarcopenia and fatty liver disease.

Authors:  Jung A Kim; Kyung Mook Choi
Journal:  Hepatol Int       Date:  2019-11-08       Impact factor: 6.047

7.  Bariatric Surgery Outcomes in Sarcopenic Obesity.

Authors:  Diego Mastino; Maud Robert; Cecile Betry; Martine Laville; Christian Gouillat; Emmanuel Disse
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

Review 8.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

Review 9.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

10.  Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.

Authors:  Daniel Cabrera; Alex Ruiz; Claudio Cabello-Verrugio; Enrique Brandan; Lisbell Estrada; Margarita Pizarro; Nancy Solis; Javiera Torres; Francisco Barrera; Marco Arrese
Journal:  Dig Dis Sci       Date:  2016-08-29       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.